News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Zhen Su: Phase III NSCLC results are out – Ivonescimab vs. Pembrolizumab!
Photo of Zhen Su
Sep 14, 2024, 12:01

Zhen Su: Phase III NSCLC results are out – Ivonescimab vs. Pembrolizumab!

Zhen Su, CEO at Marengo Therapeutics, posted the following on LinkedIn:

“Phase III NSCLC Ivonescimab (Anti-VEGF/PD-1 Bispecific) from Akeso Inc. vs. Pembrolizumab (Anti PD-1) topline results are out at WCLC. PFS HR: 0.51 H2H and benefits observed across all major subgroups. Congratulations to AKESOBIO team! Really excited to see the next-gen IO reagents (bispecific IO) continue to push the boundaries higher for better patient care.

Still more to learn why it worked so well. But for the NSCLC patients who were enrolled in the investigational arm… doubling progress free survival is what matters!”

Zhen Su: Phase III NSCLC results are out – Ivonescimab vs. Pembrolizumab!

Source: Zhen Su/LinkedIn

Akeso Inc. Anti-PD-1 anti-VEGF bispecific IO cancer ivonescimab Marengo Therapeutics next-gen IO reagents NSCLC OncoDaily Oncology pembrolizumab Phase III trial WCLC 2024 Zhen Su
Special Coverage
Blog
Nov 5, 2024, 14:24
Petra Ibum Adjah: Ending Cervical Cancer
Blog
Nov 5, 2024, 14:20
Anand Patel: Discussing novel therapies in ALL with Dr. Marcos De Lima and Dr. Raul Martinez
Insight
Nov 5, 2024, 14:18
Xiaolei Liu: New insights into lymphatic development by CXCL12/CXCR4 signaling
Blog
Nov 5, 2024, 14:01
Ravindran Kanesvaran: Chairing the 2nd National Cancer Centre Singapore Population Health Retreat
Blog
Nov 5, 2024, 13:57
OncoInfluencers to Follow on Social Media: Dr. Khaled Ghanem
Blog
Nov 5, 2024, 13:52
Yelena Janjigian: Pushing the boundaries of gastric and esophageal cancer treatment and someday prevention
Blog
Nov 5, 2024, 13:42
Jarushka Naidoo: Clinical trial concepts in thoracic oncology at the ETOP residential workshop
Career
Nov 5, 2024, 13:30
Professor Andrew Roberts has been appointed as the next editor-in-chief of Blood, ASH's prestigious journal
Insight
Nov 5, 2024, 12:37
Adding Inavolisib to Fulvestrant and Palbociclib in first line for patients with PIK3CA-Mutation
Insight
Nov 5, 2024, 12:33
Adam Weiner: Correlates between PSMA PET and MRI for clinically significant Prostate Cancer
Insight
Nov 5, 2024, 11:14
Eileen M. O’Reilly: Adjuvant mFOLFIRINOX for Resected Pancreatic Adenocarcinoma
Insight
Nov 5, 2024, 11:12
Cathy Eng: Role of ctDNA in resected liver metastasis in colorectal cancer by Koshi Kataoka et. al